Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report.
Gilly
F N
FN
Surgical Department, Centre Hospitalo-Universitaire Lyon Sud, France.
Beaujard
A
A
Bienvenu
J
J
Trillet Lenoir
V
V
Glehen
O
O
Thouvenot
D
D
Malcus
C
C
Favrot
M
M
Dumontet
C
C
Lombard-Bohas
C
C
Garbit
F
F
Gueugniaud
P Y
PY
Vignal
J
J
Aymard
M
M
Touraine Moulin
F
F
Roos
M
M
Pavirani
A
A
Courtney
M
M
D000230:Adenocarcinoma / Q000097:blood / Q000628:therapy*; D000256:Adenoviridae / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D015703:Antigens, CD / Q000097:blood; D003110:Colonic Neoplasms / Q000097:blood / Q000628:therapy; D004067:Digestive System Neoplasms / Q000097:blood / Q000628:therapy*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000097:blood / Q000235:genetics / Q000627:therapeutic use*; D007378:Interleukins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000914:Antibodies, Viral; D015703:Antigens, CD; D007376:Interleukin-2; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha